-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ATemHTzDQvvChQdQ3btqed0vBKz1eK8zq2HIvcSsRhxjpm7ekjuXey64yHDeX81F X555vtLdpuIq5nXIAerELw== 0000891618-99-001241.txt : 19990331 0000891618-99-001241.hdr.sgml : 19990331 ACCESSION NUMBER: 0000891618-99-001241 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19990326 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 19990330 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABGENIX INC CENTRAL INDEX KEY: 0001052837 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943248826 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-24207 FILM NUMBER: 99577605 BUSINESS ADDRESS: STREET 1: 7601 DUMBARTON CIRCLE CITY: FREMONT STATE: CA ZIP: 94555 BUSINESS PHONE: 5106086500 MAIL ADDRESS: STREET 1: 7601 DUMBARTON CIRCLE CITY: FREMONT STATE: CA ZIP: 94555 8-K 1 FORM 8-K 1 - -------------------------------------------------------------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) March 30, 1999 (March 26, 1999) ABGENIX, INC. ------------- (Exact name of registrant as specified in its charter) DELAWARE (State or other jurisdiction of incorporation or organization) 000-24207 94-3248826 --------- ---------- Commission File Number (I.R.S. Employer Identification Number)
7601 Dumbarton Circle Fremont, California 94555 ------------------------- (Address of principal executive offices) (510) 608-6500 -------------- (Registrant's telephone number, including area code) 2 ABGENIX, INC. FORM 8-K MARCH 30, 1999 Item 5. Other Events On March 26, 1999, Abgenix announced that it signed a research collaboration agreement with BASF Bioresearch Corporation. The press release has been filed as an exhibit to this Report on Form 8-K. 3 Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunder duly authorized. ABGENIX, INC. Date: March 30, 1999 /s/ R. SCOTT GREER ------------------------------------- R. Scott Greer President and Chief Executive Officer 4 Item 7. Financial Statements and Exhibits (c) Exhibits (in accordance with Item 601 of Regulation S-K) 99.1 Press Release of Abgenix regarding the signing of a research collaboration agreement with BASF Bioresearch Corporation. 5 ABGENIX, INC. Report on Form 8-K dated March 30, 1999 INDEX TO EXHIBITS
EXHIBIT NUMBER EXHIBIT NAME - ------------- ------------------------------------------------------------- 99.1 Press Release of Abgenix regarding the signing of a research collaboration agreement with BASF Bioresearch Corporation.
EX-99.1 2 PRESS RELEASE 1 EXHIBIT 99.1 ABGENIX ENTERS RESEARCH COLLABORATION WITH BASF FREMONT, Calif., March 26 /PRNewswire/ -- Abgenix, Inc. (Nasdaq: ABGX - news) today announced that it has signed a research collaboration agreement with BASF Bioresearch Corporation ("BASF"). Under the agreement, BASF can utilize Abgenix's XenoMouse (TM) technology to develop fully human antibodies to an undisclosed antigen target. In return, Abgenix will receive an upfront research payment and could receive additional fees and milestone payments plus royalties on future product sales by BASF, if any. BASF will be responsible for product development, manufacturing and marketing of any products developed through the collaboration. "We are pleased to add BASF, a large global pharmaceutical company, to our growing list of corporate collaborators," stated R. Scott Greer, president and chief executive officer of Abgenix. "We believe that this is evidence that the pharmaceutical industry is increasingly recognizing the value of fully human monoclonal antibodies as therapeutic products." Abgenix is a biopharmaceutical company that develops and intends to commercialize antibody therapeutic products for the treatment of a variety of disease conditions, including transplant-related diseases, inflammatory and autoimmune disorders, cardiovascular disease and cancer. Abgenix has developed XenoMouse technology, which it believes enables quick generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix has collaborative arrangements with multiple pharmaceutical and biotechnology companies involving its XenoMouse technology. In addition, Abgenix has four proprietary antibody product candidates that are under development internally, two of which are in human clinical trials. Statements made in this press release about Abgenix's XenoMouse technology, product development activities and collaborative arrangements other than statements of historical fact, are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Abgenix's patent portfolio. Please see Abgenix's public filings with the Securities and Exchange Commission for information about risks which may affect Abgenix. -----END PRIVACY-ENHANCED MESSAGE-----